Nilo Therapeutics is a biotechnology company developing a new class of medicines that harness neural circuits to restore immune homeostasis in disease. By targeting master regulator brain-body circuits that centrally control systemic inflammation, Nilo is pioneering a differentiated approach to immunomodulation with the potential to treat a wide spectrum of autoimmune and inflammatory diseases with large unmet need.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/17/25 | $101,000,000 | Series A |
Alexandria Venture Investments DCVC Bio  Gates Foundation Lux Capital TCG | undisclosed |
